Robert A. Petitt

Biography

Robert A. Petitt focuses on capital markets, securities law, mergers and acquisitions (“M&A”), and corporate governance matters for both public and private company clients. Rob advises public issuers, underwriters, and placement agents in connection with a wide variety of capital markets transactions, including initial and follow-on public offerings, at-the-market offerings, registered direct offerings, and PIPEs, and draws on his extensive securities law experience to assist with ongoing SEC reporting obligations, including proxy statements, 10-Ks, and 10-Qs. Rob also guides public company boards on a full spectrum of governance issues and best practices, including compliance with applicable Nasdaq and NYSE standards. Rob has represented buyers and sellers in a variety of complex M&A transactions and takes pride in effectively and efficiently representing his clients’ interests.

Rob works closely with the boards and management teams of public companies across a wide variety of industries, including pharmaceutical and medical device companies, software companies, less-lethal defense companies, REITs, and ancillary cannabis companies. He began his career at a Boston-based Am Law 50 firm, where he advised REITs and other public issuers on corporate governance matters and represented public company acquirers in several multibillion-dollar M&A transactions.

During law school, Rob was senior articles editor of the Boston University Law Review.

Experience

Represented a pharmaceutical company in connection with a $15 million PIPE offering and an $11.2 million public offering.
Represented a private fund in structuring and closing multiple preferred convertible stock PIPE investments.
Represented an ancillary cannabis packing company with a $36 million registered direct offering.
Represented an indoor agriculture and extraction company with a $15 million at-the-market offering and an $8.7 million confidentially marketed public offering.
Represented a pharmaceutical company in connection with preparing a shelf registration statement and conducting at-the-market and registered direct offerings off of the shelf registration statement.
Represented a medical device company in connection with a $15 million equity line of credit.
Represented a life sciences company in connection with a $4.9 million registered direct offering.
Represented the lead underwriter in a $4.0 million underwritten public offering.
Represented a media services company in connection with its acquisition by a global media company.
Represented a publicly traded pharmaceutical company in connection with multiple acquisitions of private target companies.
Represented a regional supermarket company in connection with its acquisition of eight grocery stores.